EMA — authorised 18 February 2019
- Marketing authorisation holder: SHIONOGI B.V.
- Status: approved
🇪🇺 Mulpleta in European Union
EMA authorised Mulpleta on 18 February 2019
Marketing authorisations
EMA — authorised 18 February 2019
- Application: EMEA/H/C/004720
- Marketing authorisation holder: Shionogi B.V.
- Local brand name: Mulpleo (previously Lusutrombopag Shionogi)
- Indication: Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
- Status: approved
Mulpleta in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in European Union
Frequently asked questions
Is Mulpleta approved in European Union?
Yes. EMA authorised it on 18 February 2019; EMA authorised it on 18 February 2019.
Who is the marketing authorisation holder for Mulpleta in European Union?
SHIONOGI B.V. holds the EU marketing authorisation.